在以白金为基础的化疗后,Tarlatamab用于小细胞肺癌
Giannis Mountzios1, Longhua Sun2, Byoung Chul Cho3
1Fourth Department of Medical Oncology and Clinical Trials Unit, Henry Dunant Hospital Center, Athens.
The New England journal of medicine
|June 2, 2025
概括
与化疗相比,Tarlatamab显著改善了先前接受小细胞肺癌治疗的患者的整体存活率. 这种双特异性免疫疗法显示出更好的无进展生存率和更少的严重不良事件.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 临床试验 临床试验
背景情况:
- 作为DLL3定向T细胞激活剂的Tarlatamab已经加速批准用于小细胞肺癌.
- 塔拉塔马布与化疗在复发/耐药小细胞肺癌中的疗效仍然未知.
研究的目的:
- 为了比较tarlatamab与化疗的疗效和安全性,作为小细胞肺癌的二线治疗.
主要方法:
- 第三阶段,跨国,开放标签试验比较tarlatamab与化疗 (托波特坎,卢比内克丁或阿姆鲁比辛).
- 随机分配509名患者;主要终点是整体存活率.
- 关键的二次终点包括无进展生存率和患者报告的结果.
主要成果:
- 塔拉他马布显著改善了整体存活率 (中位数为13.6个月,而8.3个月;HR为0.60;P<0.001).
- 塔拉塔马布在无进展生存和减少与癌症相关的呼吸障碍和咳方面显示出好处.
- 使用tarlatamab的3级+不良事件 (54%vs. 80%) 和停止治疗 (5%vs. 12%) 的发生率较低.
结论:
- 与化疗相比,Tarlatamab在患有白金耐药小细胞肺癌的患者中显示出更高的整体存活率.
- 塔拉他马布为这种患者群体提供了更有效,更安全的治疗选择.
相关概念视频
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K